Fierce Biotech's layoff tracker for 2026 has logged fresh job cuts at two drug developers. Novo Nordisk revealed that it has let go of 4,000 more employees, adding to the company's previously reported workforce reductions. The new figure indicates that the Danish pharmaceutical giant is still in a cost-cutting phase.
In a separate entry, Sionna Therapeutics said it has halved its staff. The company, which focuses on cystic fibrosis treatments, appears to have made a sharp strategic pivot that resulted in a significant reduction in headcount. The two cases are unrelated but together signal that workforce contraction remains common across the biotech sector this year.
Fierce Biotech also asks readers to alert its editorial team about any layoffs not yet listed, meaning the tracker is expected to grow as more companies disclose staffing changes. As with any single source, these figures reflect only what the company announced and what the tracker has compiled so far.